1. Filetti S, Durante C, Hartl D, et al. (2019) Electronic address: clinicalguidelines@esmo.org. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol, 30(12): 1856-1883. [DOI:10.1093/annonc/mdz400]

2. Nabhan F, Dedhia PH, Ringel MD (2021) Thyroid cancer, recent advances in diagnosis and therapy. Int J Cancer, 149(5): 984-992. [DOI:10.1002/ijc.33690]

3. Coca-Pelaz A, Shah JP, Hernandez-Prera JC, et al. (2020) Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review. Adv Ther, 37(7): 3112-3128. [DOI:10.1007/s12325-020-01391-1]

4. Bauer AJ (2020) Pediatric Thyroid Cancer: Genetics, Therapeutics and Outcome. Endocrinol Metab Clin North Am, 49(4): 589-611. [DOI:10.1016/j.ecl.2020.08.001]

5. Maniakas A, Zafereo M, Cabanillas ME (2022) Anaplastic Thyroid Cancer: New Horizons and Challenges. Endocrinol Metab Clin North Am, 51(2): 391-401. [DOI:10.1016/j.ecl.2021.11.020]

6. Ciarallo A, Rivera J (2020) Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update. AJR Am J Roentgenol, 215(2): 285-291. [DOI:10.2214/AJR.19.22626]

7. Angell TE, Alexander EK (2019) Thyroid Nodules and Thyroid Cancer in the Pregnant Woman. Endocrinol Metab Clin North Am, 48(3): 557-567. [DOI:10.1016/j.ecl.2019.05.003]

8. Grani G, Lamartina L, Durante C, et al. (2018) Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol, 6(6): 500-514. [DOI:10.1016/S2213-8587(17)30325-X]

9. Vinh D, Zafereo M (2021) Surgical Considerations in Thyroid Cancer: What the Radiologist Needs to Know. Neuroimaging Clin N Am, 31(3): 327-335. [DOI:10.1016/j.nic.2021.04.010]

10. Nagayama Y (2018) Thyroid Autoimmunity and Thyroid Cancer - The Pathogenic Connection: A 2018 Update. Horm Metab Res, 50(12): 922-931. [DOI:10.1055/a-0648-4593]

11. Perri F, Giordano A, Pisconti S, et al. (2018) Thyroid cancer management: from a suspicious nodule to targeted therapy. Anticancer Drugs, 29(6): 483-490. [DOI:10.1097/CAD.0000000000000617]

12. Ham J, Wang B, Po JW, et al. (2021) Cancer-associated fibroblasts (CAFs) in thyroid papillary carcinoma: molecular networks and interactions. J Clin Pathol, 74(12): 759-765. [DOI:10.1136/jclinpath-2020-207357]

13. Rajabi S, Shakib H, Dastmalchi R, et al. (2020) Metastatic propagation of thyroid cancer; organ tropism and major modulators. Future Oncol, 16(18): 1301-1319. [DOI:10.2217/fon-2019-0780]

14. Li L, Wang Z, Guo H, et al. (2023) Nanomaterials: a promising multimodal theranostics platform for thyroid cancer. J Mater Chem B，11(32): 7544-7566. [DOI:10.1039/D3TB01175E]

15. Li J, Vasilyeva E, Wiseman SM (2019) Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer. Expert Rev Anticancer Ther, 19(12): 1017-1027. [DOI:10.1080/14737140.2019.1693270]

16. McDow AD, Pitt SC (2019) Extent of Surgery for Low-Risk Differentiated Thyroid Cancer. Surg Clin North Am, 99(4): 599-610. [DOI:10.1016/j.suc.2019.04.003]

17. Rajan N, Khanal T, Ringel MD (2020) Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications. Endocrine, 70(1): 24-35. [DOI:10.1007/s12020-020-02453-8]

18. van Velsen EFS, Leung AM, Korevaar TIM (2022) Diagnostic and Treatment Considerations for Thyroid Cancer in Women of Reproductive Age and the Perinatal Period. Endocrinol Metab Clin North Am, 51(2): 403-416. [DOI:10.1016/j.ecl.2021.11.021]

19. Zhang K, Li C, Liu J, et al. (2019) DNA methylation alterations as therapeutic prospects in thyroid cancer. J Endocrinol Invest, 42(4): 363-370. [DOI:10.1007/s40618-018-0922-0]

20. Lam D, Davies L, Sawka AM (2022) Women and thyroid cancer incidence: overdiagnosis versus biological risk. Curr Opin Endocrinol Diabetes Obes, 29(5): 492-496. [DOI:10.1097/MED.0000000000000756]

21. Mahmoudian-Sani MR, Jalali A, Jamshidi M, et al. (2019) Long Non-Coding RNAs in Thyroid Cancer: Implications for Pathogenesis, Diagnosis, and Therapy. Oncol Res Treat, 42(3): 136-142. [DOI:10.1159/000495151]

22. Crenshaw ML, Goldenberg D, Bann DV (2022) Incidental Papillary Thyroid Cancer Identified During Parathyroidectomy. Ear Nose Throat J, 101(10): 657-659. [DOI:10.1177/0145561320982695]

23. Hou L, Song X (2018) "Effects of Radiofrequency Ablation on Peripheral Blood Lymphocyte Subpopulations and Cytokine Levels in Patients with Primary Liver Cancer."[J] China Medical Equipment, 15(12): 101-105.

24. Shi K, Xu D, Zheng C, et al. (2018) "Comparison of Radiofrequency Ablation and Surgical Resection in the Removal of Excessive Residual Thyroid Tissue before 131I Therapy for Differentiated Thyroid Cancer."[J] Chinese Journal of Medical Ultrasound (Electronic Edition), 15(4): 281-286.

25. Yang X, He Y (2022) "Observation of the Therapeutic Effect and Impact of Ultrasound-Guided Thyroid Radiofrequency Ablation on Patients with Thyroid Cancer." Clinical General Surgery Electronic Journal, 10(3): 37-40.

26. Lu Y, Gu G (2021) "Application of Ultrasound-Guided Radiofrequency Ablation in Thyroid Nodules."[J] Imaging Research and Medical Application, 5(24): 216-218.

27. Du Z, Dong G (2021) "Clinical Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation in the Treatment of Microscopic Papillary Thyroid Carcinoma." O[J]ncology: Basic and Clinical, 34(5): 378-381.

28. Sun P, Liang D (2018) "Efficacy of Ultrasound-Guided Radiofrequency Ablation for Microscopic Papillary Thyroid Carcinoma and Its Effects on Postoperative Stress." [J]Advances in Modern General Surgery in China, 21(3): 217-219, 222.

29. Wang H, Wu J (2021)"Effects of Radiofrequency Ablation on Thyroid Function and HSP70 Protein Expression in Patients with Benign Thyroid Nodules."[J] Practical Oncology Journal, 36(8): 1281-1284, 1304.

30. Ma D, Xi L, Zhang H (2020)"Influence of Radiofrequency Ablation on Thyroid Function in Patients with Solid Thyroid Nodules."[J] Baotou Medical College Journal, 36(6): 34-35, 73.

31. Zhao X, Shao L, Xue W, et al. (2017) "Effects of Percutaneous Microwave Ablation under Ultrasound Guidance on the Treatment of Benign Thyroid Tumors and Thyroid Hormone Levels." [J]Modern Diagnosis & Treatment, 28(21): 4054-4055.

32. Wan Y (2023) "Efficacy of Ultrasound-Guided Radiofrequency Ablation for Microscopic Papillary Thyroid Carcinoma and Its Impact on Postoperative Stress." [J]Medical Information, 36(8): 112-115.

33. Zhao X, Song M (2022) "Effects of Ultrasound-Guided Radiofrequency Ablation and Surgical Resection on the Treatment of Microscopic Papillary Thyroid Carcinoma and the Incidence of Complications." [J]Clinical Medical Research and Practice, 7(17): 105-107.

34. Gong H, Liu W, Yao Z (2019) "Observation of the Therapeutic Efficacy of Microwave Ablation and Radiofrequency Ablation under Ultrasound Guidance and Surgical Resection in the Treatment of Microscopic Papillary Thyroid Carcinoma." [J]China Cancer Clinical Rehabilitation, 26(7): 781-784.

35. Zhu B (2015)"Comparison of the Effects of Percutaneous Microwave Treatment and Radiofrequency Ablation under Ultrasound Guidance on Postoperative Stress Response in the Treatment of Microscopic Papillary Thyroid Carcinoma." [J]China Health Industry, (20): 168-169.

36. Bao Xiaoyao (2021)"Analysis of the Safety and Long-Term Follow-Up Results of Ultrasound-Guided Radiofrequency Ablation in the Treatment of Thyroid Papillary Carcinoma."[J] China Medical Engineering, 29(11): 128-130.

37. Zhang X (2020) "Analysis of the Efficacy of Ultrasound-Guided Radiofrequency Ablation in the Treatment of Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma." [J]China Medical Device Information, 26(3): 120-122.

38. Zhang W (2022)"Clinical Effects of Ultrasound-Guided Percutaneous Microwave Ablation and Surgical Resection in the Treatment of Microscopic Papillary Thyroid Carcinoma Patients."[J] World Journal of Integrated Traditional and Western Medicine, 8(2): 146-149.

39. Zhou H, Li G, Chen Y (2020) "Treatment of Microscopic Papillary Thyroid Carcinoma with Ultrasound-Guided Percutaneous Microwave Ablation."[J] Modern Medicine, 48(3): 373-378.

40. Shao C (2011) "Changes in Peripheral Blood T Lymphocyte Subpopulations and Serum Immunoglobulins during the Perioperative Period in Patients with Thyroid Cancer." [J]Chinese Primary Health Care, 18(21): 2895-2896.

41. Zhang L, Xi Y, You L, et al. (2018) "Effects of TSH Suppressive Therapy on Serum Tg, VEGF, TSGF, CD44V6, sIL-2R, and T Lymphocyte Subpopulation Levels in Differentiated Thyroid Cancer Patients after Surgery[J]." Journal of Hainan Medical University, 24(2): 242-245.

42. Shen R, Xiong G, Hou M, et al. (2021) Effect of hepatic arterial chemoembolization combined with radiofrequency ablation in the treatment of hepatocellular carcinoma and its effect on serum T lymphocyte subpopulations and transforming growth factor β_1 levels [J]. Chinese Journal of Contemporary Medicine, 28(26): 130-133.

43. Xu B, Ghossein RA (2020) Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): An Update. Head Neck Pathol, 14(2): 303-310. [DOI:10.1007/s12105-019-01124-z]

44. Lorusso L, Cappagli V, Valerio L, et al. (2021) Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. Int J Mol Sci, 22(6): 3117. [DOI:10.3390/ijms22063117]

45. Wang J, Zhanghuang C, Jin L, et al. (2022) Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study. BMC Geriatr, 22(1): 736. [DOI:10.1186/s12877-022-02761-w]

46. Al-Qurayshi Z, Foggia MJ, Pagedar N, et al. (2020) Thyroid cancer histological subtypes based on tumor size: National perspective. Head Neck, 42(9): 2257-2266. [DOI:10.1002/hed.26159]

47. Estorch M, Mitjavila M, Muros MA, et al. (2019) Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. Rev Esp Med Nucl Imagen Mol (Engl Ed)9, 38(3):195-203. [DOI:10.1016/j.remnie.2018.12.004]

48. Schuster-Bruce J, Sargent P, Madden B, et al. (2022) A systematic review of endotracheal stenting in patients with locally advanced thyroid cancer. Clin Otolaryngol, 47(3): 414-423. [DOI:10.1111/coa.13923]

49. Mahmoudian-Sani MR, Alghasi A, Saeedi-Boroujeni A, et al. (2019) Survivin as a diagnostic and therapeutic marker for thyroid cancer. Pathol Res Pract, 215(4): 619-625. [DOI:10.1016/j.prp.2019.01.025]

50. Shafabakhsh R, Asemi Z, Mansournia MA, et al. (2023) CircRNAs: A Novel Strategy in Diagnosis and Treatment of Thyroid Cancer. Curr Mol Med, 23(8): 737-747. [DOI:10.2174/1566524022666220701141914]

51. Vaisman F, Tuttle RM (2019) Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am, 48(1): 99-108. [DOI:10.1016/j.ecl.2018.11.002]

52. Hernandez-Prera JC (2020) The evolving concept of aggressive histological variants of differentiated thyroid cancer. Semin Diagn Pathol，37(5): 228-233. [DOI:10.1053/j.semdp.2020.03.002]

53. Nishino M (2020) Thyroid pathology: Controversies and best practices. Semin Diagn Pathol，37(5): 211-212. [DOI:10.1053/j.semdp.2020.07.004]

54. Boukheris H, Bachir Bouiadjra N (2022) Thyroid cancer incidence and trends by demographic and tumor characteristics in Oran, Algeria: 1993-2013, a population-based analysis. Eur J Cancer Prev, 31(3): 301-308. [DOI:10.1097/CEJ.0000000000000699]